Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.

摘要: Newly developed IRMAs to measure the plasma concentrations of renin and prorenin were validated for clinical use compared with a classical enzyme kinetic assay. The involve two monoclonal antibodies, one that reacts equally well recognizes but only minimally. Prorenin reactivity second antibody was enhanced by adding inhibitor, Remikiren, plasma. complex this active-site ligand undergoes conformational change, whereby is converted into form cannot be differentiated from IRMA. linear working range assay 4.0-3000 mU/L. concentration calculated subtracting result obtained without Remikiren (i.e., renin) plus prorenin). No more than 2% present in detected as renin. interassay CVs quantification 18%, 13%, 8% at low, medium, high concentrations, respectively. CV both low concentrations. IRMA results highly correlated those an healthy subjects; patients such conditions primary hyperaldosteronism, renovascular hypertension, low-, medium-, high-renin essential hypertension; women undergoing gonadotropin stimulation.